, Tracking Stock Market Picks
Enter Symbol:

down 99.99 %


Posted on: Monday,  Nov 12, 2007  9:25 AM ET by Merriman Curhan Ford

Merriman Curhan Ford rated Buy BIONOVO INC (OTCBB: BNVIQ) on 11/12/2007, when the stock price was $11.00. Since
then, BIONOVO INC has lost 99.99% as of 08/14/2015's recent price of $0.00.
If you would have followed this Merriman Curhan Ford's recommendation on BNVIQ, you would have lost 99.99% of your investment in 2832 days.

Bionovo, Inc. is a clinical stage drug discovery and development company focusing on women?s health and cancer. The Company designs drugs derived from botanical sources, which have mechanisms of action. The Company?s drug candidate, Menerba, represents a class of receptor sub-type selective estrogen receptor modulator (SERM) for the treatment of vasomotor symptoms of menopause, or hot flashes. The Company has designed Menerba to selectively modulate estrogen receptor beta (ERβ). In preclinical studies, Menerba inhibited tumor growth, as well as bone resorption known to cause osteoporosis, which is developed during menopause. The Company was developing BZL101, an oral anti-cancer agent for advanced breast cancer during the year ended December 31, 2008. BZL101 is designed to take advantage of the metabolism of cancer cells. BZL101 inhibits glycolysis, a metabolic pathway on which cancer cells rely.

We occupy a unique niche among our investment banking peers: we offer our clients both traditional sell-side equity research and primary market research, and we focus on high-potential sectors such as CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. Our institutional and corporate clients get the best of both worlds: expertise from our analysts and access to experts through our Panel Intelligence platform.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/12/2007 9:25 AM Buy
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy